GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...

He’s openly criticized the FDA and has called for an end to the regulatory oversight of many health products, including ...

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products. Read More on GB:GSK: GSK NewsMORE Related Stocks Indices ...

The U.S. Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups, as an ...

Optoelectronic devices and components are those electronic devices that operate on both light and electrical currents. This can include electrically driven light sources such as laser diodes and ...

Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price ...

By prioritising local production of essential pharmaceuticals, the government seeks not only to secure the healthcare needs ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...